Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | AGXT | P21549 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.30 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5454226 | 0.87 | SKP2 (0.44) | ALDH1A1TDP1CYP3A4USP14KDM4E | |
| SCHEMBL4432103 | 0.84 | ALDH1A1 (0.35) | ALDH1A1TDP1CASP1PARP1CYP3A4 | |
| SCHEMBL1527572 | 0.83 | IDO1 (0.42) | ALDH1A1PARP1CYP3A4USP14MAPT | |
| SCHEMBL22425843 | 0.83 | NPC1 (0.37) | PARP1USP14SMN1; SMN2IDO1GAA | |
| SCHEMBL8115822 | 0.83 | ALOX5AP (0.36) | USP14IDO1GAA | |
| SCHEMBL31584756 | 0.81 | GAA (0.56) | ALDH1A1TDP1PARP1CYP3A4KDM4E | |
| SCHEMBL31371309 | 0.81 | CYP4F2 (0.40) | CASP1USP14TSHR | |
| SCHEMBL15152700 | 0.81 | CYP4F2 (0.40) | CASP1USP14TSHR | |
| SCHEMBL15108599 | 0.81 | USP14 (0.34) | ALDH1A1USP14NPC1 | |
| SCHEMBL5462778 | 0.80 | USP14 (0.33) | USP14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349865-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2200612-B1 | INHIBITORS OF JANUS KINASES | SCHERING CORP (US) | 2012-08-08 | — | — | EP | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| EP-2200612-A1 | INHIBITORS OF JANUS KINASES | Merck Sharp & Dohme Corp. (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009035575-A1 | INHIBITORS OF JANUS KINASES | MERCK & CO., INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-6555541-B1 | P2X7 receptor antagonists for treatment of inflammatory respiratory system disorders such as asthma; for example, 2-(3,4-Difluorophenylamino)-N-(2-methyl-5-piperazin-1-yl-methyl-phenyl) -acetamide, trihydrochloride | ASTRAZENECA UK LIMITED (GB) | 2003-04-29 | — | — | US | disclosed |
| EP-1185522-A1 | SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AstraZeneca AB (SE) | 2002-03-13 | — | — | EP | disclosed |
| WO-2000071529-A1 | SUBSTITUTED PHENYL COMPOUNDS WITH IMMUNOSUPPRESSING ACTIVITY AND PHARMACEUTICAL COMPOSITIONS | ASTRAZENECA AB (SE) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197634-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | ALDH1A1 3244/4885TDP1 1401/4885CASP1 2016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.